2020-09-17
Essai de phase IIb/III réussi dans la sclérose en plaque progressive
Neurology
Il s’agit du premier médicament ayant montré un effet positif sur les formes progressives de la SEP qui touchent 100 000 personnes en France.
Source(s) :
Communiqué de presse AB Science : publié le 14 septembre 2020 ;

Last press reviews
Does education really make a difference in lower back pain?

By Ana Espino | Published on september 9, 2025 | 2 min read<br>...
Spinal cord injury & physiotherapy: What does the science say?

By Ana Espino | Published on september 9, 2025 | 2 min read
Burnout: The hidden mechanisms of a very real ailment

By Lila Rouland | Published September 8, 2025 | 2 min read <br><br>...